Why is the CSL share price on the slide today?

Shares in the ASX healthcare giant are holding their own on Tuesday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The ASX 200 is in the green so far this Tuesday
  • Not so the CSL share price although, curiously, it's holding up rather well
  • That's despite CSL shares trading ex-dividend today

It's been a wavering start to the trading day for the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday. At the time of writing, the ASX 200 has gained just 0.09% and is back below 6,860 points. But it's still ahead of the CSL Limited (ASX: CSL) share price.

CSL shares are down 0.1% at the time of writing. The ASX 200 healthcare giant closed at $294.80 a share yesterday. It opened at $294.42 this morning and is now trading at $294.50 at the time of writing.

This doesn't exactly appear to be a strong session for CSL shares, given the ASX 200 is slightly outperforming these gains so far. But it is if we factor in what has just happened to the CSL share price. The company has just traded ex-dividend today for the upcoming final dividend payment for FY22.

When CSL revealed its full-year earnings report for FY22 last month, it declared a final dividend of US$1.18 per share. That translates to $1.68 per share, partially franked at 10%.

As we discussed yesterday, this was flat in US dollar terms on last year's final dividend. But thanks to favourable currency exchange rates, ASX investors will enjoy a 5.6% boost from what they received last year.

The dividend is scheduled to be paid out next month on 5 October, so investors will have to wait until then to see the cash.

A scientist examining test results.

Image source: Getty Images

CSL share price rises, despite ex-dividend date

But CSL shares traded ex-dividend for this upcoming final payment today. That means that any new investors in CSL from today are not eligible to receive this dividend.

Normally, when a company trades ex-dividend, we see a corresponding drop in the company's share price. This reflects the reality that CSL shares are less valuable, thanks to the fact that the dividend is no longer available for new investors.

Today, we have seen no such obvious drop. That means that CSL is having a fairly strong day – if it weren't for the ex-dividend date, the company would probably be enjoying gains.

So arguably, this is a very happy day for CSL investors.

At the current CSL share price, this ASX 200 healthcare share has a dividend yield of 1.02%.

Motley Fool contributor Sebastian Bowen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose

Clarity Pharmaceuticals reports further progress in its SECuRE prostate cancer trial, showing strong PSA responses and new complete responses at…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade

Second quarter net sales of DAYBUE increased 30%.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why this ASX healthcare stock is at the cusp of a 'Transformational Opportunity' – Expert

This ASX healthcare stock is one to watch.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
ASX Share Market News

Earnings preview: can Cochlear shares rebound?

A decade low share price meets a make-or-break result.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Healthcare Shares

Why I'm watching CSL shares like a hawk in August

A low valuation will look very different depending on what management says about the year ahead.

Read more »

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

A make-or-break result for Australia's fallen biotech giant.

Read more »